Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Novel therapeutics in hepatocellular carcinoma: how can we make progress?

Kelley RK, Venook AP.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e137. Review.

2.

Emerging targeted strategies in advanced hepatocellular carcinoma.

Finn RS.

Semin Liver Dis. 2013 Feb;33 Suppl 1:S11-9. doi: 10.1055/s-0033-1333632. Epub 2013 Mar 1. Review.

PMID:
23457035
3.

Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.

Palmer DH, Johnson PJ.

Cancer Metastasis Rev. 2015 Sep;34(3):497-509. doi: 10.1007/s10555-015-9580-2. Review.

PMID:
26250585
4.

Systemic therapies for hepatocellular carcinoma.

Ge S, Huang D.

Drug Discov Ther. 2015 Oct;9(5):352-62. doi: 10.5582/ddt.2015.01047. Review.

5.

Molecular targeted therapy for hepatocellular carcinoma: current and future.

Shin JW, Chung YH.

World J Gastroenterol. 2013 Oct 7;19(37):6144-55. doi: 10.3748/wjg.v19.i37.6144. Review.

6.

Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future.

Patel A, Sun W.

Curr Treat Options Oncol. 2014 Sep;15(3):380-94. doi: 10.1007/s11864-014-0291-7. Review.

PMID:
24838298
7.

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review.

Qi XS, Guo XZ, Han GH, Li HY, Chen J.

World J Gastroenterol. 2015 May 14;21(18):5445-53. doi: 10.3748/wjg.v21.i18.5445. Review.

8.

Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST.

Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J.

Semin Liver Dis. 2014 Nov;34(4):444-55. doi: 10.1055/s-0034-1394143. Epub 2014 Nov 4. Review.

PMID:
25369306
9.

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW.

J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26.

PMID:
23980090
10.

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Llovet JM, Hernandez-Gea V.

Clin Cancer Res. 2014 Apr 15;20(8):2072-9. doi: 10.1158/1078-0432.CCR-13-0547. Epub 2014 Mar 3. Review.

11.

Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

Hollebecque A, Malka D, Ferté C, Ducreux M, Boige V.

Eur J Cancer. 2015 Feb;51(3):327-39. doi: 10.1016/j.ejca.2014.12.005. Epub 2015 Jan 2. Review.

PMID:
25559615
12.

Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma.

Sato K, Mori M.

Curr Med Chem. 2011;18(28):4375-88. Review.

PMID:
21861817
13.

Systemic treatment of hepatocellular carcinoma: dawn of a new era?

Zhu AX.

Ann Surg Oncol. 2010 May;17(5):1247-56. doi: 10.1245/s10434-010-0975-6. Epub 2010 Apr 20. Review.

PMID:
20405329
14.
15.

Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile.

Facciorusso A, Antonino M, Del Prete V, Amoruso A, Neve V, Barone M.

Curr Drug Saf. 2015;10(3):202-7. Review.

PMID:
25994808
16.

Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.

Germano D, Tinessa V, Barletta E, Cannella L, Daniele B.

Drugs Aging. 2013 Nov;30(11):887-92. doi: 10.1007/s40266-013-0124-6. Review.

PMID:
24097332
17.

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL.

J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26.

PMID:
23980084
18.

Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.

Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ.

World J Gastroenterol. 2014 Aug 14;20(30):10249-61. doi: 10.3748/wjg.v20.i30.10249. Review.

19.

Targeted therapy for liver cancer: updated review in 2012.

Kudo M.

Curr Cancer Drug Targets. 2012 Nov 1;12(9):1062-72. Review.

PMID:
22920326
20.

Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.

Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O.

Invest New Drugs. 2015 Jun;33(3):729-39. doi: 10.1007/s10637-015-0237-3. Epub 2015 Apr 12.

PMID:
25861764

Supplemental Content

Support Center